Patents Assigned to Takeda Pharmaceutical Company Limited
  • Anti-MIF immunohistochemistry
    Patent number: 11402388
    Abstract: The present invention pertains to the specific detection of MIF, in particular oxMIF, in tissues. A detection method is provided which uses immunohistochemistry and wherein specific anti-oxMIF antibodies are used.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: August 2, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Michael Thiele, Randolf Kerschbaumer, Dirk Voelkel, Patrice Douillard, Friedrich Scheiflinger, Alexander Schinagl
  • Nucleic acids encoding plasma kallikrein binding proteins
    Patent number: 11401346
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: August 2, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan
  • Fused heterocyclic compound
    Patent number: 11390634
    Abstract: Provided is a compound represented by the following formula, or a salt thereof: [wherein each symbol is as defined herein.].
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: July 19, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Youichi Kawakita, Takuto Kojima, Noriyuki Nii, Yoshiteru Ito, Nobuki Sakauchi, Hiroshi Banno, Xin Liu, Koji Ono, Keisuke Imamura, Shinichi Imamura
  • Bispecific antibodies against plasma kallikrein and Factor XII
    Patent number: 11390687
    Abstract: Described herein are bispecific antibodies that bind to plasma kallikrein (pKal) and Factor XII and methods of producing and using such bi-specific antibodies for treating diseases or disorders associated with the contact system, e.g., hereditary angioedema or thrombosis.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stephen R. Comeau, Andrew Nixon, Niksa Kastrapeli, Jon A. Kenniston, Gregory P. Conley, Shauna Mason, Allison P. Lindberg, Kristopher Kopacz, Burt Adelman
  • Method of treating inflammatory bowel disease
    Patent number: 11389533
    Abstract: The invention provides methods for identifying patients who do not adequately respond to vedolizumab therapy and treating these patients with a personalized treatment approach using vedolizumab.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: July 19, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Maria Rosario, Morris Barocas, Marc R. Gastonguay
  • METHODS AND APPARATUSES FOR MODELING, SIMULATING, AND TREATING HEREDITARY ANGIOEDEMA
    Publication number: 20220223299
    Abstract: Aspects of the present application provide for methods and apparatuses for modeling, simulating, and treating hereditary angioedema (HAE). According to some aspects, a quantitative systems pharmacology (QSP) model is provided for simulating the efficacy of drug intervention under context of HAE pathophysiology. The QSP model may comprise a plurality of individual models including one or more PK models and/or one or more PD models for simulating drug exposure, target engagements and acute attack rate in HAE patients. A virtual patient population representing a plurality of virtual patients may be developed and input into the QSP model for executing a virtual clinical trial. In some embodiments, the QSP model may be used evaluate a response of the contact system and/or an effectiveness of a therapeutic intervention for treating HAE.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 14, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Rangaraj Narayanan, Hoa Q. Nguyen, Daniel J. Sexton
  • Heteroaryl plasma kallikrein inhibitors
    Patent number: 11370803
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Jeremy Mark Travins, Sarah Jocelyn Fink, John Mark Ellard, Alastair Rae
  • Assays for determining plasma kallikrein system biomarkers
    Patent number: 11372002
    Abstract: Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 28, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman
  • MATRIX COMPOSITION
    Publication number: 20220195367
    Abstract: The present invention provides means for producing an organoid close to an organ in a living body and capable of secretion of a plasma protein and immune response. A matrix composition of the present invention provided as such means includes: (1) a first matrix containing one or more cells selected from the group consisting of vascular cells, nerve cells, and blood cells; and (2) a second matrix containing to cells constituting an organ and/or an organoid, in which the first matrix envelops the second matrix, and the first matrix has at least one opening.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 23, 2022
    Applicants: Public University Corporation Yokohama City University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori TAKEBE, Norikazu SAIKI
  • Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
    Patent number: 11357832
    Abstract: The present invention, provides a method of treating cognitive impairment of Hunter syndrome. Among other things, the present invention provides a method comprising a step of administering intrathecally to a subject in need of treatment a recombinant iduronate-2-sulfatase (I2S) enzyme at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce declining of one or more cognitive, adaptive, motor, and/or executive functions relative to a control.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: June 14, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Ann Barbier, Thomas Mccauley, Charles W. Richard, III
  • Inhibitors of plasma kallikrein and uses thereof
    Patent number: 11352356
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: June 7, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Nikolaos Papaioannou, Sarah Jocelyn Fink, Thomas Allen Miller, Gerald Wayne Shipps, Jr., Jeremy Mark Travins, David Edward Ehmann, Alastair Rae, John Mark Ellard
  • PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR PREVENTING HEREDITARY ANGIOEDEMA ATTACK
    Publication number: 20220169749
    Abstract: Provided herein are plasma kallikrein antibodies binding to active plasma kallikrein and methods of using such antibodies in preventing hereditary angioedema attack or reducing the rate of hereditary angioedema attack.
    Type: Application
    Filed: October 13, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yung Chyung, Burt Adelman, Daniel J. Sexton
  • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS
    Publication number: 20220170936
    Abstract: The present disclosure provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.
    Type: Application
    Filed: October 1, 2021
    Publication date: June 2, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Ryan Faucette, Jon A. Kenniston, Gregory P. Conley, Andrew Nixon, Christopher TenHoor, Burt Adelman, Yung Chyung
  • Prevention and reduction of blood loss
    Patent number: 11344610
    Abstract: Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 31, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Robert Charles Ladner, Arthur Charles Ley, Shirish Hirani, Anthony Williams
  • Metabolite biomarkers for diseases associated with the contact activation system
    Patent number: 11340237
    Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: May 24, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Daniel J. Sexton, Malini Viswanathan, Ryan Faucette, Tripti Gaur
  • NUTRITION COMPOSITION
    Publication number: 20220135938
    Abstract: The present invention provides a means for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells. The nutrition composition according to the present invention is a nutrition composition for suppressing formation and/or proliferation of undesired cells derived from stem cells in a cell population containing cells differentiated from stem cells, the nutrition composition containing at least one essential amino acid selected from the group consisting of isoleucine, leucine, methionine, lysine, phenylalanine, tryptophan, threonine and histidine except valine, and optionally containing a non-essential amino acid(s).
    Type: Application
    Filed: October 11, 2019
    Publication date: May 5, 2022
    Applicants: Public University Corporation Yokohama City University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori TAKEBE, Yasunori NIO
  • Heterocyclic compound and application thereof
    Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Syringe
    Patent number: 11318258
    Abstract: The present invention suppresses the amount of fluid pushed out from an injection needle when confirming whether air has been pushed out of the injection needle. Provided is a syringe that comprises: a cylinder 20; an injection needle 22; a needle base 24; an injection needle cover 26; and a plunger rod 28. The needle base 24 communicates between the inside of the cylinder 20 and the inside of the injection needle 22. The injection needle cover 26, when extended from a folded state, surrounds the injection needle 22. The injection needle cover 26 comprises an injection needle surrounding part. The injection needle surrounding part has at least one cutout 130 in a section facing the needle base 24 and covering the needle base, such that the needle base 24 can be identified from the outside.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: May 3, 2022
    Assignees: TAKEDA PHARMACEUTICAL COMPANY LIMITED, YOSHINO KOGYOSHO CO., LTD., ARTE CORPORATION
    Inventors: Kiyoshi Okajima, Yuki Imanishi, Jiichi Arai, Yusuke Chuma
  • Display screen with a transitional graphical user interface
    Patent number: D953348
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: May 31, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: McCay Barnes, Martha Schuster
  • Pusher foot for a fluid delivery device
    Patent number: D956205
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: June 28, 2022
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shekhar Nimkar, Adam C. Fox, Jessica Diane Young, Beverly Anne Piatt, James Alan Prescott, William G. Atterbury